Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) decapeptide analog. As a potent GnRH receptor agonist, its activity is stronger than that of natural GnRH. Clinically, triptorelin primarily inhibits the pituitary gland's secretion of gonadotropins through continuous administration, thereby suppressing testicular and ovarian function and lowering sex hormones (such as testosterone or estrogen) to castration levels.
Currently, triptorelin is widely used clinically to treat the following diseases:
Prostate Cancer: Applicable for palliative treatment and clinical diagnosis of advanced hormone-dependent prostate cancer.
Endometriosis: Used to treat endometriosis (stages I to IV) both inside and outside the genitals.
Uterine Fibroids: Used for preoperative treatment of uterine fibroids to reduce fibroid size and correct anemia.
Female Infertility: Used for pituitary downregulation in assisted reproductive technologies such as in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT).
Central precocious puberty: Used to inhibit excessive secretion of pituitary gonadotropins in children and delay skeletal maturation.
In 1971, foreign scientists successfully isolated and extracted natural GnRH gonadotropin-releasing hormone from the hypothalamus of animals, clarifying its biological mechanism of action and laying the scientific foundation for subsequent synthetic analogs. Due to the short half-life and poor stability of natural GnRH, it was difficult to meet the needs of routine experiments and applications. Subsequent researchers continuously optimized the molecular structure, developing a more stable and more compatible synthetic analog-triptorelin-by replacing specific amino acid sites.
Triptorelin was initially optimized and finalized by overseas research institutions, and subsequently, a specialized biotechnology company completed the process implementation and mass production optimization. It was officially launched overseas in 1986. After decades of process iteration, triptorelin synthesis technology is now mature and its quality is controllable. It is a widely used GnRH-modified peptide raw material in the global scientific research field, extensively used in various reproductive mechanism studies, peptide comparison experiments, and related research projects. It is also a regular essential product in the foreign trade scientific research peptide market.
To maximize the preservation of peptide structural integrity and activity, and avoid problems such as oxidation, moisture absorption, and degradation, this product must be stored in a sealed container under strict conditions:
1. Short-term use (1-3 months): Refrigerate in a sealed container at 2℃-8℃, avoiding light, moisture, and oxygen throughout the process, and avoiding frequent opening to prevent exposure to air;
2. Long-term storage (more than 3 months): It is recommended to store in a -20℃ low-temperature frozen environment, sealed and protected from light, to effectively prevent tryptophan oxidation and peptide chain degradation;
3. Daily storage should be kept away from high temperature, humidity, and direct sunlight. Do not leave it open at room temperature for extended periods. Use it as soon as possible after opening, and avoid repeated freeze-thaw cycles.
Under standard storage conditions of complete sealing, protection from light, and compliant temperature and humidity, the shelf life of this product is 24 months. Prolonged open storage at room temperature, repeated freeze-thaw cycles, or storage in humid and high-temperature environments will accelerate the loss of product activity, cause powder deterioration, significantly shorten the usage cycle, and affect experimental results.
Long-acting sustained-release technology: Utilizing advanced microsphere technology, the drug is released slowly and uniformly in the body. Long-acting formulations (e.g., once a month or every three months) can significantly reduce the number of hospital visits and injections, alleviating patient suffering and financial burden.
Potential castration effect: As a potent GnRH receptor agonist, it can rapidly and stably reduce testosterone to castration levels, effectively inhibiting the growth of hormone-dependent tumors.
High safety and compliance: Compared to traditional oral estrogen castration therapy, it avoids cardiovascular toxicity and thrombosis risks; compared to surgical castration, it preserves the patient's physical integrity and improves quality of life.
Breakthrough in domestic substitution: Domestically produced microsphere formulations have high drug loading and fewer excipients, reducing the initial burst release effect of the drug, resulting in more stable blood drug concentrations and improved medication safety.
**Risk of Worsening Initial Symptoms:** In the initial stages of treatment (the first few weeks), due to a transient increase in hormone levels, a very small number of patients may experience a worsening of symptoms such as bone pain, urinary tract obstruction, or spinal cord compression. Close medical monitoring is required for these high-risk patients during the initial treatment phase.
**Adverse Reaction Monitoring:** Due to the suppression of sex hormones, patients often experience hot flashes, decreased libido, erectile dysfunction, vaginal dryness, and mood changes. Long-term use requires monitoring for the risk of decreased bone mineral density.
**Contraindications:** This medication is contraindicated in pregnant women, breastfeeding women, and those allergic to GnRH analogues. Women must confirm they are not pregnant before treatment.
**Regular Follow-up:** During treatment, regular monitoring of blood pressure, blood sugar, electrolytes, sex hormone levels, and bone mineral density is necessary.
**Drug Interactions:** If you are currently taking antiarrhythmic drugs, antibiotics, or other prescription medications, please inform your doctor in advance.
Hot Tags: low-priced triptorelin/gnrh cas no.: 57773-63-4, China low-priced triptorelin/gnrh cas no.: 57773-63-4 manufacturers, suppliers, factory
